CalciMedica, Inc. Common Stock Market Cap ($9.90 Million)
Market Cap & Net Worth: CalciMedica, Inc. Common Stock (CALC)
CalciMedica, Inc. Common Stock market cap. CalciMedica, Inc. Common Stock (NASDAQ:CALC) has a market capitalization of $9.90 Million ($9.90 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26977 globally and #5608 in its home market, demonstrating a 26.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CalciMedica, Inc. Common Stock's stock price $1.46 by its total outstanding shares 15746416 (15.75 Million).
CalciMedica, Inc. Common Stock Market Cap History (2020–2026)
CalciMedica, Inc. Common Stock market cap history from 2020 to 2026. Data shows change from $6.40 Billion to $22.99 Million (-56.41% CAGR). Check latest CalciMedica, Inc. Common Stock stock price today for real-time trading data and today's change.
Index Memberships
CalciMedica, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #752 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2465 of 3165 |
Weight: CalciMedica, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CalciMedica, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CalciMedica, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CalciMedica, Inc. Common Stock (CALC) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CALC by Market Capitalization
Companies near CalciMedica, Inc. Common Stock in the global market cap rankings as of October 31, 2026. See CalciMedica, Inc. Common Stock net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to CalciMedica, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of CalciMedica, Inc. Common Stock (2020–2026)
Market capitalization of CalciMedica, Inc. Common Stock from 2020 to today. Between 2020 and today, CalciMedica, Inc. Common Stock's market cap moved from $6.40 Billion to $ 22.99 Million, with a yearly change of -56.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $22.99 Million | -77.85% |
| 2025 | $103.77 Million | +86.16% |
| 2024 | $55.74 Million | +23.78% |
| 2023 | $45.03 Million | -59.14% |
| 2022 | $110.22 Million | -72.68% |
| 2021 | $403.42 Million | -93.69% |
| 2020 | $6.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of CalciMedica, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.90 Million USD |
| MoneyControl | $9.90 Million USD |
| MarketWatch | $9.90 Million USD |
| marketcap.company | $9.90 Million USD |
| Reuters | $9.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more